“In 2023, we made significant progress toward expanding the opportunities for avutometinib combination therapies across RAS/MAPK driven cancers and I am extremely proud of the team’s accomplishments,” said Dan Paterson, president and chief executive officer of Verastem Oncology. “2024 is expected to be a pivotal year with the planned NDA submission for our avutometinib and defactinib combination in recurrent LGSOC, and multiple clinical data readouts across our programs including initial data from the RAMP 205 trial in metastatic pancreatic cancer and data from the combination with G12C inhibitors in NSCLC. We look forward to continuing to deliver results across our programs.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VSTM:
- Verastem receives Orphan Drug Designation from FDA for avutometinib
- Verastem treatment of low grade serous ovarian cancer granted orphan designation
- Verastem Outlines Strategic Priorities for 2024
- Verastem Shareholders Approve Executive Option Exchange Plan
- Verastem granted fast track designation for Avutometinib+Sotorasib in NSCLC
